RxDoctor Payments Data

Kenneth Sharlin, MD

Neurology · Ozark, MONPI 1790749182

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2021 at $13,793 and has fallen 77.4% since, to $3,115 in 2025.

$38,447in general payments, 2019–2025

Across 803 payments — averaging $47.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Biohaven Pharmaceuticals, Inc.$6K
  • Biogen$4K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Titan Surgical Group, LLC$2K
  • plus $12K from 44 others
$4,292,855in research payments, 2019–2025

Across 198 payments — averaging $21,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2M
  • Novartis$855K
  • Sanofi$692K
  • Biogen$297K
  • Hoffmann-la Roche Limited$167K
  • AbbVie$121K
  • plus $132K from 8 others

What the payments were for

  • Consulting fees$2,8257%
  • Speaking & faculty fees$13,90036%
  • Travel & lodging$4,86013%
  • Food & beverage$14,69338%
  • Education$2,1696%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,447 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$64,799
Medicare patients
214
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone11$159,145
Kesimpta PenOfatumumab14$154,145
Avonex Pen (4 Pack)Interferon Beta-1a11$105,416
IngrezzaValbenazine Tosylate12$97,179
AustedoDeutetrabenazine16$87,682
Aimovig AutoinjectorErenumab-Aooe80$72,006
Nurtec OdtRimegepant Sulfate38$69,334
UbrelvyUbrogepant30$51,053
Emgality PenGalcanezumab-Gnlm43$38,684
BriviactBrivaracetam12$19,992
SunosiSolriamfetol Hcl12$10,529
OngentysOpicapone14$9,295
Carbidopa-LevodopaCarbidopa/Levodopa238$7,337
ProgesteroneProgesterone, Micronized307$6,858
Lacosamide37$4,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$1,136$106,47326 claims
Teva Pharmaceuticals USA, Inc.Austedo$660$87,68216 claims
PfizerNurtec Odt$491$69,33438 claims
AbbVieUbrelvy, Armour Thyroid$8,883$51,95852 claims
UCB, Inc.Briviact$49$19,99212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 381 neurology providers in Missouri.

Other neurology in Ozark

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →